Display options
Cite
Matthaei S, Reaney M, Mathieu C, et al. Patients with Type 2 Diabetes Initiating Exenatide Twice Daily or Insulin in Clinical Practice: CHOICE Study. Diabetes Ther. 2012;3(1):6doi: 10.1007/s13300-012-0006-7.
Matthaei, S., Reaney, M., Mathieu, C., Ostenson, C. G., Krarup, T., Guerci, B., Kiljanski, J., Petto, H., Bruhn, D., & Theodorakis, M. (2012). Patients with Type 2 Diabetes Initiating Exenatide Twice Daily or Insulin in Clinical Practice: CHOICE Study. Diabetes therapy : research, treatment and education of diabetes and related disorders, 3(1), 6. https://doi.org/10.1007/s13300-012-0006-7
Matthaei, Stephan, et al. "Patients with Type 2 Diabetes Initiating Exenatide Twice Daily or Insulin in Clinical Practice: CHOICE Study." Diabetes therapy : research, treatment and education of diabetes and related disorders vol. 3,1 (2012): 6. doi: https://doi.org/10.1007/s13300-012-0006-7
Matthaei S, Reaney M, Mathieu C, Ostenson CG, Krarup T, Guerci B, Kiljanski J, Petto H, Bruhn D, Theodorakis M. Patients with Type 2 Diabetes Initiating Exenatide Twice Daily or Insulin in Clinical Practice: CHOICE Study. Diabetes Ther. 2012 Nov;3(1):6. doi: 10.1007/s13300-012-0006-7. Epub 2012 Jun 20. PMID: 22714818; PMCID: PMC3508107.
Copy Download .nbib Format: NLM
Share it on

Diabetes Ther. 2012 Nov;3(1):6. doi: 10.1007/s13300-012-0006-7. Epub 2012 Jun 20.

Patients with Type 2 Diabetes Initiating Exenatide Twice Daily or Insulin in Clinical Practice: CHOICE Study.

Diabetes therapy : research, treatment and education of diabetes and related disorders

Stephan Matthaei, Matthew Reaney, Chantal Mathieu, Claes-Göran Ostenson, Thure Krarup, Bruno Guerci, Jacek Kiljanski, Helmut Petto, David Bruhn, Michael Theodorakis

Affiliations

  1. Diabetes-Zentrum Quakenbrück, Fachabteilung fur Diabetologie, Stoffwechsel und Endokrinologie am Christlichen Krankenhaus, Klinisches Diabeteszentrum der DDG, Akademisches Lehrkrankenhausder Medizinischen Hochschule Hannover, Danziger Str.10, 49610, Quakenbruck, Germany, [email protected].

PMID: 22714818 PMCID: PMC3508107 DOI: 10.1007/s13300-012-0006-7

Abstract

INTRODUCTION: Changes to Treatment and Outcomes in Patients with Type 2 Diabetes Initiating Injectable Therapy (CHOICE) is a European prospective, observational cohort study assessing time to, and factors associated with, a significant change in therapy after type 2 diabetes patients initiate their first injectable glucose-lowering therapy, and these patients' clinical outcomes over 24 months. The authors report baseline data and factors associated with the injectable treatment regimen.

METHODS: Demographic, clinical, and healthcare resource-use data were collected at initiation of injectable therapy and analyzed using univariate tests between cohorts and multivariate logistic regression analysis for treatment.

RESULTS: Overall, 1,177 patients initiated exenatide twice daily (b.i.d.) and 1,315 initiated insulin. Most patients were recruited by secondary-care physicians. Univariate analyses revealed statistically significant differences between the characteristics of patients who initiated exenatide b.i.d. and patients who initiated insulin. On multivariate analysis, higher body mass index [BMI; 5 kg/m(2) higher: odds ratio (OR) 2.10, 95% confidence intervals (CI) 1.84-2.40], lower glycated hemoglobin (HbA(1c); 1% higher: OR 0.77, 95% CI 0.69-0.86), and lower age (5 years older: OR 0.82, 95% CI 0.76-0.88) were the variables most strongly associated with increased probability of receiving exenatide b.i.d. (P < 0.0001). Patients initiating exenatide b.i.d. had a mean BMI of 35.3 ± 6.5 kg/m(2), HbA(1c) of 8.4 ± 1.4%, and age of 58 ± 10 years, compared with 29.7 ± 5.4 kg/m(2), 9.2 ± 1.9%, and 64 ± 11 years, respectively, in patients initiating insulin (P < 0.0001). Other characteristics significantly associated with exenatide b.i.d. initiation were "disinhibited eating" (Diabetes Health Profile-18), lower random blood glucose, less blood glucose self-monitoring, lower low-density lipoprotein cholesterol, and receipt of diet/exercise advice.

CONCLUSIONS: Patients who initiated exenatide b.i.d. were on average younger and more obese with lower HbA(1c) than those initiating insulin.

References

  1. Diabetes Care. 2005 May;28(5):1083-91 - PubMed
  2. Diabetes Care. 2004 Nov;27(11):2628-35 - PubMed
  3. Eur Heart J. 2007 Jan;28(1):88-136 - PubMed
  4. Diabet Med. 2007 Dec;24(12):1412-8 - PubMed
  5. Curr Med Res Opin. 2008 Jan;24(1):275-86 - PubMed
  6. Diabetes Metab. 2010 Nov;36(5):381-8 - PubMed
  7. Clin Ther. 2007 Nov;29(11):2333-48 - PubMed
  8. Curr Med Res Opin. 2009 Mar;25(3):691-700 - PubMed
  9. Ann Intern Med. 2005 Oct 18;143(8):559-69 - PubMed
  10. J Gen Intern Med. 2007 Apr;22(4):453-8 - PubMed
  11. Clin Ther. 2007 Jun;29(6 Pt 1):1284-92 - PubMed
  12. Diabetologia. 2007 Feb;50(2):259-67 - PubMed
  13. Diabetes Care. 2009 Jan;32(1):193-203 - PubMed
  14. Diabetes Care. 2004 Jul;27(7):1535-40 - PubMed
  15. Emerg Med J. 2003 Jan;20(1):54-60 - PubMed
  16. Diabet Med. 2000 Aug;17(8):572-80 - PubMed
  17. J Biopharm Stat. 2007;17(1):1-13; discussion 15-7, 19-21, 23-7 passim - PubMed
  18. Curr Med Res Opin. 2009 Mar;25(3):777-86 - PubMed
  19. Endocr Pract. 2009 Sep-Oct;15(6):540-59 - PubMed

Publication Types